Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide biosimilar - Intas Pharmaceuticals

Next Previous
Drug Profile

Teriparatide biosimilar - Intas Pharmaceuticals

Alternative Names: INTG8; Parathyroid hormone - Intas Pharmaceuticals; PTH - Intas Pharmaceuticals; Terifrac

Latest Information Update: 25 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis
  • Phase III Fracture

Most Recent Events

  • 25 Jan 2023 Intas Pharmaceuticals completes a phase I bioequivalence trial in Healthy volunteers (SC) as of January 2023 (CTRI-2020-10-028627)
  • 28 Sep 2021 Teriparatide biosimilar is still in phase III trials for Fracture in India (SC, Injection)
  • 22 Oct 2020 Intas Pharmaceuticals plans a phase I bioequivalence trial in healthy volunteers in India in October 2020 (SC) (CTRI2020-10-028627),

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top